Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies (NCT05488548)

🧪 Interventions in This Study

• EP31670 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (6 Sites)

• Mayo Clinic Arizona — Phoenix, Arizona
• Mayo Clinic Florida — Jacksonville, Florida
• Dana Farber Cancer Institute — Boston, Massachusetts
• Mayo Clinic Rochester — Rochester, Minnesota
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• University of Washington/Fred Hutchinson Cancer Center — Seattle, Washington

📞 Contact the Study Coordinator

Phone: (561) 865-6098

Email: studies@epigenetix.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Castrate Resistant Prostate Cancer

• Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer — San Francisco, California

Explore by condition: All Castrate Resistant Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.